Generic Depakote wins FDA approval

A generic version of Depakote, an anti-seizure medication that clinicians also use to treat migraine headaches and bipolar disorder, received FDA approval yesterday. Abbott Laboratories originally manufactured the drug.

The approval was for delayed-release tablets and will have the same black box warning that the branded drug has, which includes warnings about liver and pancreas risks, as well as the risk of birth defects. 

Eight different companies received licensure to begin marketing the drug, including Sun Pharmaceuticals and Teva Pharmaceuticals.

- here's the FDA release
- read the story at WebMD
- see more from the Washington Post

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.